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This paper summarizes the workshop content on how the integration of large biomolecular and 
clinical datasets can enhance the field of population health via translational informatics. Large 
volumes of data present diverse challenges for existing informatics technology, in terms of 
computational efficiency, modeling effectiveness, statistical computing, discovery algorithms, 
and heterogeneous data integration. While accumulating large ‘omics measurements on subjects 
linked with their electronic record remains a challenge, this workshop focuses on non-trivial 
linkages between large clinical and biomolecular datasets. For example, exposures and clinical 
datasets can relate through zip codes, while comorbidities and shared molecular mechanisms can 
relate diseases. Workshop presenters will discuss various methods developed in their respective 
labs/organizations to overcome the difficulties of combining together such large complex datasets 
and knowledge to enable the translation to clinical practice for improving health outcomes.      
Keywords: Translational informatics, biomolecular, clinical, population health, big data, workshop 
 
1.  Introduction, Background, and Motivation 
The field of population health is rapidly moving to the forefront of research, with the 
advancement of biotechnologies and growth of international collaborations enabling the vast 
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accumulation of population health data. The availability of such data crossing multiple 
dimensions, from electronic health records, lifestyles, environmental factors, genetics, to 
genomics, is promising for further advancing the field via translational bioinformatics. A 
growing trend is the integrative data collection that encompasses all aspects (both genetic and 
non-genetic factors) of the same participants, exemplified by eMERGE1, UK Biobank2, and All of 
US program3, among many others in specific domain and specialties.4, 5 
 
However, large volumes of data present diverse challenges for existing informatics technology, 
in terms of computational efficiency, modeling effectiveness, statistical computing, discovery 
algorithms, and heterogeneous data integration. These new demands also call for bridging the 
gap between disciplines among statistical genetics, health informatics, and bioinformatics. 
Successful endeavors in these areas will dramatically enhance the understanding of the 
genetic/epigenetic mechanisms of complex diseases and their interplay with the environment and 
lifestyles as well as foster the translation of these findings to clinical practice to improve health 
outcomes.6, 7 
 
In this era of Big Data science, the number of opportunities to study large-scale molecular and 
population datasets together is flourishing. The developers of PheWAS8 were among the pioneers 
to transform heterogeneous and sparsely-annotated clinical data for systematic analysis with 
densely-annotated SNP arrays. Combining this knowledge with publicly-available data from 
sources, such as UK Biobank2 that offers health information on over 500,000 participants, not 
only promotes Big Data analytics, but also demonstrates the feasibility of such studies. 
 
This paper summarizes how the integration of large datasets, such as biomolecular and clinical 
data, can advance the field of population health via translational informatics as well as focuses 
on current approaches to overcome the challenges of combining these complex data.    
 
2. Workshop Presenters 
The three-hour workshop is organized in the form of six presentations, including two keynote 
speakers, followed by a discussion session, which will be moderated by Dr. Yves A. Lussier.  
 
Keynote speakers are: 
• Atul Butte, MD, PhD (Priscilla Chan and Mark Zuckerberg Distinguished Professor, 
University of California, San Francisco) 
• Jason H. Moore, PhD, FACMI (Edward Rose Professor of Informatics, University of 
Pennsylvania) 
 
Additional speakers include: 
• Francesca Vitali, PhD (Research Assistant Professor, The University of Arizona) 
• Lara M. Mangravite, PhD (President, Sage Bionetworks) 
• Serghei Mangul, PhD (QCB Postdoctoral Fellow, University of California, Los Angeles) 
• Marina Sirota, PhD (Assistant Professor, University of California, San Francisco) 
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3. Presenters’ Abstracts 
Translating a trillion points of data into therapies, diagnostics, and new precision medicine 
Atul Butte, MD, PhD (University of California, San Francisco) 
There is an urgent need to take what we have learned in our new “genome era” and use it to 
create a new system of precision medicine, delivering the best preventative or therapeutic 
intervention at the right time, for the right patients. Dr. Butte's lab at the University of California, 
San Francisco builds and applies tools that convert trillions of points of molecular, clinical, and 
epidemiological data -- measured by researchers and clinicians over the past decade and now 
commonly termed “big data” -- into diagnostics, therapeutics, and new insights into disease. 
Several of these methods or findings have been spun out into new biotechnology companies. Dr. 
Butte, a computer scientist and pediatrician, will highlight his lab’s recent work, including the 
use of publicly-available molecular measurements to find new uses for drugs including new 
therapies for autoimmune diseases and cancer, discovering new druggable targets in disease, the 
evaluation of patients and populations presenting with whole genomes sequenced, integrating 
and reusing the clinical and genomic data that result from clinical trials, discovering new 
diagnostics include blood tests for complications during pregnancy, and how the next generation 
of biotech companies might even start in your garage. 
 
Enabling translational bioinformatics with accessible artificial intelligence 
Jason H. Moore, PhD (University of Pennsylvania) 
Artificial intelligence (AI) is a rapidly maturing technology that has the potential to accelerate 
translational bioinformatics and precision medicine using both basic science and clinical data. 
While AI has become widespread, many commercial AI systems are not yet accessible to 
individual researchers nor the general public due to the deep knowledge of the systems required 
to use them. We believe that AI has matured to the point where it should be an accessible 
technology for everyone. We present an ongoing project whose goal is to deliver an open-source, 
user-friendly AI system that is specialized for machine learning analysis of complex data in the 
biomedical and health care domains. 
 
Novel and emerging data fusion strategies for integrating health and biomolecular data 
Francesca Vitali, PhD (The University of Arizona) 
Over the last few years, biomedical research and clinical practice have experienced incredible 
growth in terms of both the amount and variety of data being collected and leveraged for 
different types of analysis. This represents a great opportunity to increase our knowledge about 
many biological mechanisms as well as improve the medical process. However, not all big data 
is created equal, complicating the integration and analysis of such large datasets. For example, 
clinical record data is highly heterogeneous, sparsely annotated, and contains several 
measurement types and unstructured text fields comprised of ambiguous statements as well as 
varying levels of certainty, whereas genomic and imaging data are crisp, homogeneous, densely 
annotated data with a low cardinality of distinct variables. Nowadays, the development of novel 
methodologies capable of integrating population health data with biomolecular data is crucial, 
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not only for enabling translational and clinical research, but for developing more effective patient 
care. However, integrating these data are particularly challenging when the molecular 
measurements are not conducted on individual subjects. In order to take full advantage of the 
wide spectrum of biomedical data available, advanced data integration tools need to be 
developed. In this context, we will discuss novel and emerging data fusion strategies for 
integrating health and biomolecular data to develop new research hypotheses and conduct 
predictive and data interpolation operations. These methods include approaches that (i) take into 
account comprehensive drug-exposure histories of individuals derived from healthcare data, 
while also including genetic, environmental, and lifestyle variabilities for each individual; (ii) 
integrate electronic medical records with biobank data to identify new disease pathways; (iii) 
combine multi-omic profiling with clinical factors from large cohorts; and (iv) perform crisp 
integration of bimolecular data whilst leveraging population measurements (e.g., counties, 
medication, diseases).  
 
Open practices to advance biomedicine through data-intensive science 
Lara M Mangravite, PhD (Sage Bionetworks)  
Open science practices in bio-computing have been promoted over the past 10 years under the 
premise that these approaches can improve confidence and, therefore, speed advancement of 
biomedical hypotheses stemming from computational research. In that time, we have observed 
wide adoption of open practices including those focused on open data, open commons(es), open 
source software, and open access publishing. Although many of these efforts help to establish 
confidence in research observations amongst computationally-savvy researchers, they often fail 
to support the wider acceptance necessary to inform trajectories of biological inquiry and/or to 
promote adoption for use in clinical care. Here, we discuss complementary mechanisms to 
further support the advancement of biocomputational hypotheses, including those developed 
using emerging digital health technologies, through the transfer and translation of knowledge 
across research domains.   
 
Seeing Beyond the Target: Constructing germline research cohorts from clinical tumor 
sequencing 
Serghei Mangul, PhD (University of California, Los Angeles)  
Tens of thousands of cancer patients have had their tumors sequenced to identify clinically 
actionable mutations. In addition to saving lives, this activity has produced valuable research 
data sets leading to significant discoveries in basic and translational domains. However, the 
targeted nature of clinical tumor sequencing has a limited research scope, especially with respect 
to germline genetics. In this work, we address this problem by developing a software platform 
(SBT: Seeing Beyond the Target) that mines discarded tumor sequences to produce rich research 
level data including genome-wide germline genotypes, T and B cell receptor sequences, rDNA 
and mtDNA copy number, and HLA types. These features have been demonstrated as potential 
prognostic indicators in research studies, and our methods now make them available in large-
scale clinical cohorts. We validate the accuracy of our tool, by comparison, to deeply sequenced 
cohorts and show its utility through replication of known genetic associations. We provide a free 
downloadable cloud implementation and demonstrate its efficiency by constructing the largest 
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germline-somatic cohort produced to date (n>20,000), more than doubling the size of The 
Cancer Genome Atlas. We believe that SBT will greatly increase the research potential of 
clinical tumor data sets and provide a bridge between the germline and somatic research 
communities. SBT is freely available at https://github.com/smangul1/seeing.beyond.target/wiki 
 
Leveraging population level molecular, environmental and clinical data to study adverse 
pregnancy outcomes 
Marina Sirota, PhD (University of California, San Francisco) 
Given the wealth and availability of genomic, clinical and environmental exposure data, 
computational integrative methods provide a powerful opportunity to identify population-
specific determinants of disease. In this talk, I will discuss our efforts to develop computational 
methods and integrate large-scale genomic, transcriptomic and environmental exposure datasets 
to elucidate factors that affect preterm birth (PTB). Preterm birth, or the delivery of an infant 
prior to 37 weeks of gestation, is a major health concern. Infants born prematurely, comprising of 
about 12% of the US newborns, have elevated risks of neonatal mortality and a wide array of 
health problems. In our work, we leverage the rich multi-omic, clinical and environmental 
variation data to advance our understanding of biology of preterm birth as it relates to all 
populations. Our findings further inform precise population-specific diagnostic and therapeutic 
strategies bringing us closer to applying precision medicine to this important biomedical 
problem. 
 
4. Conclusion 
This workshop will highlight a number of methods, strategies, and tools currently being 
developed for integrating population health data with biomolecular data to mitigate the diverse 
challenges of existing informatics technology. The ability to combine these big data across 
various domains to conduct meaningful and interpretable analysis is critical for improving 
overall population health outcomes. 
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